
|Videos|November 14, 2021
ImprimisRx offers a look at three new products in the pipeline
Author(s)David Hutton, Alex Delaney-Gesing
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
Advertisement
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting, including:
- Moxi-Brom (moxifloxacin hydrochloride 0.5% and bromfenac sodium sesquihydrate 0.075%)
- Klarity-CL drops (cyclosporine 0.1% / loteprednol etabonate 0.2% ophthalmic suspension)
- Tim-Brim-Dor-Bim (prednisolone acetate 1%, gatifloxacin 0.5%, bromfenac 0.075%).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Phase 3 NORTHSTAR Trial Launches for Gildeuretinol in Stargardt Disease
2
Self-Screening for Ocular Surface Malignancies Using a Smartphone
3
Rising Star: Introducing Viha Vig, MBChB
4
Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ)
5





















